Three dozen institutional investors are urging the boards at several of the world’s largest pharmaceutical companies to establish concrete metrics for linking executive compensation with policies that widen access to medicines to low- and middle-income countries.
In a series of letters, the investors asked the heads of board compensation committees to examine such steps as voluntary licensing agreements and technology transfer for generic production; supply chain performance for improving access to poor countries; transparency surrounding pricing policies; and access plans that focus specifically on diseases that affect people in these countries.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
